Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
| Image |  |
|---|---|
| Description | scientific article published on 26 August 2019 |
| Author/s |
author: Johan Bodegard Jan W Eriksson |
| Publication date | August 26, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |